Primary aldosteronism

Hormone Research

Volumn 71, Issue SUPPL. 1, 2009, Pages 8-12

  Carey, Robert M ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Hypertension; Hypokalemia; Mineralocorticoid hormone; Primary aldosteronism

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID; RENIN; SPIRONOLACTONE;

ADRENAL BLOOD FLOW; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIC ALKALOSIS; KIDNEY DYSFUNCTION; MUSCLE WEAKNESS; NEPHROGENIC DIABETES INSIPIDUS; PARESTHESIA; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; STROKE; TETANY;

HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MODELS, BIOLOGICAL;

EID: 58549105491     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178029     Document Type: Conference Paper

References (11)

1. Viengchareun S, Menuet D, Martineire L, Munier M, Tallec LP, Lombes M: The mineralocorticoid receptor: insights into molecular and (patho)physiological biology. Nucl Recept Signal 2007;5:e102.
2. Funder JW, Carey RM, Fardella C, Gomez-Sanchea CE, Mantero F, Stowasser M, Young WF Jr, Montori VM: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; [Epub ahead of print].
3. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giachetyti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F: A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-2300.
4. Stowasser M, Gordon RD: The aldosteronerenin ratio for screening for primary aldosteronism. Endocrinologist 2004;14:267-276.
5. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissman P: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-896.
6. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902.
7. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giachetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo C, Rizzoni D, Rossi E, Semplicini A, Agabiti-Tosei E, Pessina AC, Mantero F: Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone producing adenoma. J Hypertens 2007;25:1433-1442.
8. McMahon GT, Dluhy RG: Glucocorticoid-remediable aldosteronism. Cardiol Rev 2004;12:44-48.
9. Young WF Jr: Role for adrenal venous sampling in primary aldosteronism. Surgery 2004;136:1227-1235.
10. Young WF Jr: Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007:66:607-618.
11. Young WF Jr: Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003;144:2208-2213.